106 related articles for article (PubMed ID: 16454748)
1. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Wick W; Naumann U; Weller M
Curr Pharm Des; 2006; 12(3):341-9. PubMed ID: 16454748
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma.
Birch JL; Coull BJ; Spender LC; Watt C; Willison A; Syed N; Chalmers AJ; Hossain-Ibrahim MK; Inman GJ
Cell Signal; 2020 Aug; 72():109638. PubMed ID: 32320860
[TBL] [Abstract][Full Text] [Related]
3. The TGF-β Family in Glioblastoma.
Golán-Cancela I; Caja L
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256140
[TBL] [Abstract][Full Text] [Related]
4. Cellular context-dependent "colors" of transforming growth factor-beta signaling.
Ikushima H; Miyazono K
Cancer Sci; 2010 Feb; 101(2):306-12. PubMed ID: 20067465
[TBL] [Abstract][Full Text] [Related]
5. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma revisited: from neuronal-like invasion to pacemaking.
Heuer S; Winkler F
Trends Cancer; 2023 Nov; 9(11):887-896. PubMed ID: 37586918
[TBL] [Abstract][Full Text] [Related]
7. TGF-β signaling in liver metastasis.
Marvin DL; Heijboer R; Ten Dijke P; Ritsma L
Clin Transl Med; 2020 Nov; 10(7):e160. PubMed ID: 33252863
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma: Not Just Another Cancer.
Fine HA
Cancer Discov; 2024 Apr; 14(4):648-652. PubMed ID: 38571415
[TBL] [Abstract][Full Text] [Related]
9. Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.
Yuan Y; Su Y; Wu Y; Xue Y; Zhang Y; Zhang Y; Zheng M; Chang T; Qu Y; Zhao T
Front Oncol; 2023; 13():1229905. PubMed ID: 37671057
[TBL] [Abstract][Full Text] [Related]
10. High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray.
Feng X; Zhang L; Ke S; Liu T; Hao L; Zhao P; Tu W; Cang S
Oncol Lett; 2020 Sep; 20(3):2356-2368. PubMed ID: 32782553
[TBL] [Abstract][Full Text] [Related]
11. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
12. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
[TBL] [Abstract][Full Text] [Related]
13. Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.
Li J; Wang F; Wang G; Sun Y; Cai J; Liu X; Zhang J; Lu X; Li Y; Chen M; Chen L; Jiang C
Oncotarget; 2017 Apr; 8(16):26256-26268. PubMed ID: 28412740
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors.
Morandi A; Taddei ML; Chiarugi P; Giannoni E
Front Oncol; 2017; 7():40. PubMed ID: 28352611
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.
Seliger C; Meyer AL; Renner K; Leidgens V; Moeckel S; Jachnik B; Dettmer K; Tischler U; Gerthofer V; Rauer L; Uhl M; Proescholdt M; Bogdahn U; Riemenschneider MJ; Oefner PJ; Kreutz M; Vollmann-Zwerenz A; Hau P
Cell Cycle; 2016 Jul; 15(13):1755-66. PubMed ID: 27163626
[TBL] [Abstract][Full Text] [Related]
16. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
Eder K; Kalman B
Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
[TBL] [Abstract][Full Text] [Related]
17. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
18. Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.
Cheng S; Guo J; Yang Q; Yang X
Med Oncol; 2015 Mar; 32(3):47. PubMed ID: 25636509
[TBL] [Abstract][Full Text] [Related]
19. Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.
Cheng S; Guo J; Yang Q; Han L
Tumour Biol; 2015 Feb; 36(2):915-9. PubMed ID: 25307974
[TBL] [Abstract][Full Text] [Related]
20. Induction of transforming growth factor beta receptors following focal ischemia in the rat brain.
Pál G; Lovas G; Dobolyi A
PLoS One; 2014; 9(9):e106544. PubMed ID: 25192322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
